I-Mab Receives Nasdaq Deficiency Notice for Minimum Bid Price

An announcement from I-MAB ( (IMAB) ) is now available.

On March 21, 2025, I-Mab announced it received a Nasdaq deficiency notice on March 19, 2025, for not meeting the $1.00 minimum bid price requirement. This notice does not immediately affect the listing of I-Mab’s American Depositary Shares, which continue to trade on the Nasdaq Global Market. The company has until September 15, 2025, to regain compliance by ensuring its ADSs meet or exceed $1.00 per share for ten consecutive business days. I-Mab is evaluating options to address this issue and intends to regain compliance, although there is no assurance of success. The notice does not impact I-Mab’s business operations or SEC reporting requirements.

More about I-MAB

I-Mab is a US-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment. The company operates in Rockville, Maryland, and Short Hills, New Jersey.

YTD Price Performance: -2.31%

Average Trading Volume: 352,584

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $65.47M

Learn more about IMAB stock on TipRanks’ Stock Analysis page.